Wednesday, April 30

Join us for an in-depth exploration of prescription drug advertising, focusing on the current state of FDA promotional rules and the FDA’s position on scientific exchanges protected by the First Amendment. We will delve into the FDA’s final guidance on disseminating off-label information on approved products and examine the effects of the new administration on these critical topics. This program is designed to provide valuable insights and practical strategies for navigating the complex regulatory landscape of prescription drug advertising.